ROS1 and non-small cell lung carcinoma: Similar to the challenges faced when targeting other driver mutations in NSCLC, optimal treatment of ROS1-positive NSCLCs not only requires an inhibitor that can overcome mechanisms of resistance but also one that penetrates through the BBB to treat brain metastases.